BiotechTube

atorvastatin + atorvastatin + atorvastatin

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias

Trial Timeline

Dec 1, 2003 → Oct 1, 2004

NCT ID
NCT00645424

About atorvastatin + atorvastatin + atorvastatin

atorvastatin + atorvastatin + atorvastatin is a approved stage product being developed by Pfizer for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT00645424. Target conditions include Hyperlipidemias.

What happened to similar drugs?

1 of 4 similar drugs in Hyperlipidemias were approved

Approved (1) Terminated (0) Active (3)
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00645151ApprovedCompleted
NCT00645424ApprovedCompleted
NCT00647543ApprovedCompleted

Competing Products

5 competing products in Hyperlipidemias

See all competitors
ProductCompanyStageHype Score
Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
39
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SLN360 + PlaceboMedpacePhase 1
26
Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3
34